Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Michael O'Riordan

January 09, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Opinion CV Team Dispatch

May 2025 Dispatch for the CV Team

L.A. McKeown

May 20, 2025

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Daily News

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Michael O'Riordan

July 07, 2023

News Daily News

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

Michael O'Riordan

May 03, 2023

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for January 2018

Shelley Wood

January 31, 2018

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

Advertisement

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Year in Review: Top Prevention Stories of 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

May 2025 Dispatch for the CV Team

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

August 2024 Dispatch for the CV Team

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

TCTMD’s Top 10 Most Popular Stories for January 2018

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content